National AIDS Memorial to Launch 50-State AIDS Memorial Quilt Virtual Exhibition in Conjunction with World AIDS Day
09 oct. 2020 14h49 HE
|
National AIDS Memorial
San Francisco, Oct. 09, 2020 (GLOBE NEWSWIRE) -- The National AIDS Memorial is announcing a virtual exhibition of the AIDS Memorial Quilt (the Quilt) that will feature more than 10,000 Quilt panels...
Vivent Health Announces Partnership with National AIDS Memorial
23 juin 2020 11h45 HE
|
National AIDS Memorial
Milwaukee, June 23, 2020 (GLOBE NEWSWIRE) -- Vivent Health announced today a long-term partnership with the National AIDS Memorial, a nonprofit devoted to the remembrance of people lost to AIDS that...
National AIDS Memorial Awards $50,000 in Scholarships to Young Leaders Committed to Helping End the HIV/AIDS Epidemic
24 oct. 2019 12h17 HE
|
National AIDS Memorial
San Francisco, Oct. 24, 2019 (GLOBE NEWSWIRE) -- The Pedro Zamora Young Leaders Scholarship, a program of the National AIDS Memorial, has awarded ten undergraduate students a total of $50,000 in...
Immune Therapeutics Signs Memorandum of Understanding for Distribution of Lodonal™ in Côte d’Ivoire and acquires COPP for Côte d’Ivoire; Company Plans for Approval of Lodonal in Côte d’Ivoire in 2017
31 mai 2017 09h14 HE
|
Immune Therapeutics, Inc.
ORLANDO, Fla., May 31, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a specialty pharmaceutical company focused on developing and commercializing our novel patented, affordable,...
CORRECTING and REPLACING: Immune Therapeutics, Inc.
22 mai 2017 09h24 HE
|
Immune Therapeutics, Inc.
In a release issued under the same headline earlier today by Immune Therapeutics, Inc. (OTCQB:IMUN), the headline has been corrected to read "Immune Therapeutics Announces NAFDAC Approval...
Immune Therapeutics Announces NAFDAC Approval of Lodonal™ for the Treatment of HIV in Nigeria
22 mai 2017 08h42 HE
|
Immune Therapeutics, Inc.
Highlights: National Agency for Food and Drug Administration and Control (“NAFDAC”) approval paves way for Immune Therapeutics’ first significant revenue channel Immune Therapeutics’ goal to capture...
Immune Therapeutics, Inc. Announces Expansion of Patent Portfolio
30 mars 2017 09h45 HE
|
Immune Therapeutics, Inc.
ORLANDO, Fla., March 30, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics Inc. (OTCQB:IMUN), a clinical-stage biopharmaceutical company developing therapies for a range of conditions using LodonalTM,...
Immune Therapeutics Clears Critical Certification Milestone
02 févr. 2017 09h40 HE
|
Immune Therapeutics, Inc.
Immune Therapeutics Receives Approval for Lodonal™ from theDominican Republic’s Ministry of Health and Social Assistance ORLANDO, Fla., Feb. 02, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics,...
UPDATE -- Immune Therapeutics Issues Special Letter to Shareholders
30 janv. 2017 10h48 HE
|
Immune Therapeutics, Inc.
Company Expects to Report Initial Revenues in First Half of 2017 and Achieve Profitability by Year-End Company to Host Investor Conference Call to Discuss Positive Developments ORLANDO, Fla.,...
Immune Therapeutics Issues Special Letter to Shareholders
30 janv. 2017 08h40 HE
|
Immune Therapeutics, Inc.
Company Expects to Report Initial Revenues in First Half of 2017 and Achieve Profitability by Year-End Company to Host Investor Conference Call to Discuss Positive Developments ORLANDO, Fla.,...